Pharma turns cold shoulder to UK

Roche and Merck Serono recently sized up their chances to pass muster with the UK's cost-effectiveness regulators and decided to give NICE a pass. Analysts say that the clinical- and cost-effectiveness evaluators at NICE have been turning an increasingly skeptical eye on some of the expensive biologics coming their way. And that helped persuade both big pharma companies to forget about making full submissions to NICE on Avastin and Erbitux. Article

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.